Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 7/20 | 0.62 |
| ▸ | ELOC | Q15369 | 2/20 | 0.62 |
| ▸ | ELOB | Q15370 | 2/20 | 0.62 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.61 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.57 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.55 |
| ▸ | NAMPT | P43490 | 4/20 | 0.55 |
| ▸ | EGFR | P00533 | 4/20 | 0.55 |
| ▸ | AR | P10275 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18530412 | 1.00 | VHL (0.62) | VHLELOCELOBLRRK2PRMT5 | |
| SCHEMBL18530416 | 1.00 | VHL (0.62) | VHLELOCELOBLRRK2PRMT5 | |
| SCHEMBL18591877 | 0.96 | VHL (0.62) | VHLELOCELOBLRRK2PRMT5 | |
| SCHEMBL18530426 | 0.95 | VHL (0.60) | VHLELOCELOBLRRK2PRMT5 | |
| SCHEMBL18530428 | 0.95 | VHL (0.60) | VHLELOCELOBLRRK2PRMT5 | |
| SCHEMBL25414216 | 0.95 | VHL (0.60) | VHLELOCELOBLRRK2PRMT5 | |
| SCHEMBL18551121 | 0.94 | LRRK2 (0.60) | VHLELOCELOBLRRK2PRMT5 | |
| SCHEMBL18530434 | 0.94 | LRRK2 (0.58) | VHLELOCELOBLRRK2PRMT5 | |
| SCHEMBL18530436 | 0.94 | LRRK2 (0.58) | VHLELOCELOBLRRK2PRMT5 | |
| SCHEMBL31228127 | 0.88 | VHL (0.73) | VHLELOCELOBHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | VHL 11/4885ELOC 251/4885ELOB 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.